mutated Ligand Binding Site gene DataBase





About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for FHL3
Gene summary
Basic gene Info.Gene symbolFHL3
Gene namefour and a half LIM domains 3
CytomapUCSC genome browser: 1p34
Type of geneprotein-coding
DescriptionFHL-3LIM-only protein FHL3SLIM-2four and a half LIM domains protein 3skeletal muscle LIM-protein 2
Modification date20141207
dbXrefs MIM : 602790
Ensembl : ENSG00000183386
HPRD : 09101
Vega : OTTHUMG00000004434
ProteinUniProt: Q13643
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_FHL3
BioGPS: 2275
PathwayNCI Pathway Interaction Database: FHL3
Pathway Commons: FHL3
ContextiHOP: FHL3
ligand binding site mutation search in PubMed: FHL3
UCL Cancer Institute: FHL3
Assigned class in mutLBSgeneDBC: This gene just belongs to mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez

Ligand binding site mutations for FHL3
Lollipop-style diagram of mutations at LBS in amino-acid sequence.
We represented ligand binding site mutations only. (You can see big image via clicking.)
: non-synonymous mutation on LBS, Circle size denotes number of samples.

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.

Protein structure related information for FHL3
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for FHL3 from PDB

Differential gene expression and gene-gene network for FHL3
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of FHL3 and the right PPI network was created from samples without mutations in the LBS of FHL3. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Phenotype information for FHL3
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Pharmacological information for FHL3
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of FHL3 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS

Conservation information for LBS of FHL3
Multiple alignments for Q13643 in multiple species
LBSAA sequence# speciesSpecies
C101AFSSQCSACGE3Homo sapiens, Bos taurus, Mus musculus
C104SQCSACGETVM3Homo sapiens, Bos taurus, Mus musculus
C126TWHEHCFLCSG3Homo sapiens, Bos taurus, Mus musculus
C129EHCFLCSGCEQ3Homo sapiens, Bos taurus, Mus musculus
C132FLCSGCEQPLG3Homo sapiens, Bos taurus, Mus musculus
C153HYCVPCYENKF3Homo sapiens, Bos taurus, Mus musculus
C162KFAPRCARCSK3Homo sapiens, Bos taurus, Mus musculus
C165PRCARCSKTLT3Homo sapiens, Bos taurus, Mus musculus
C185PWHRECLVCTG3Homo sapiens, Bos taurus, Mus musculus
C188RECLVCTGCQT2Homo sapiens, Bos taurus
C188RECLVCTGCKT1Mus musculus
C191LVCTGCQTPLA2Homo sapiens, Bos taurus
C191LVCTGCKTPLA1Mus musculus
C209DEDPYCVACFG1Homo sapiens
C209EDDPYCVTCFG1Bos taurus
C209DDDPYCVACFG1Mus musculus
C212PYCVACFGELF2Homo sapiens, Mus musculus
C212PYCVTCFGELF1Bos taurus
C28DSGPYCVPCYD2Homo sapiens, Mus musculus
C40TFANTCAECQQ3Homo sapiens, Bos taurus, Mus musculus
C43NTCAECQQLIG3Homo sapiens, Bos taurus, Mus musculus
C65HFHEGCFRCCR3Homo sapiens, Bos taurus, Mus musculus
C68EGCFRCCRCQR3Homo sapiens, Bos taurus, Mus musculus
C71FRCCRCQRSLA3Homo sapiens, Bos taurus, Mus musculus
C89DSELLCNDCYC2Homo sapiens, Bos taurus
C89DSELLCNECYC1Mus musculus
C92LLCNDCYCSAF2Homo sapiens, Bos taurus
C92LLCNECYCTAF1Mus musculus
H123GGQTWHEHCFL3Homo sapiens, Bos taurus, Mus musculus
H182RDQPWHRECLV3Homo sapiens, Bos taurus, Mus musculus
H62EDRHFHEGCFR3Homo sapiens, Bos taurus, Mus musculus

Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas